Actively Recruiting
Kelulut Honey for Allergic Conjunctivitis and Dry Eye Symptoms
Led by Universiti Sains Malaysia · Updated on 2025-12-09
72
Participants Needed
1
Research Sites
49 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if oral Kelulut honey works to improve eye symptoms in adults with allergic conjunctivitis. It will also look at how safe Kelulut honey is when taken as a daily supplement. The main questions it aims to answer are: 1. Does oral Kelulut honey reduce itchy, red, watery eyes and dry eye symptoms in people with allergic conjunctivitis? 2. Does oral Kelulut honey improve tear film stability and the health of conjunctival goblet cells (special cells on the eye surface that help keep the eye moist)? 3. What side effects or medical problems do participants have when taking Kelulut honey? Researchers will compare oral Kelulut honey to a honey-flavoured placebo syrup (a look-alike drink that does not contain Kelulut honey) to see if Kelulut honey is more effective than placebo for treating eye symptoms in allergic conjunctivitis. Participants will: 1. Take either oral Kelulut honey or a honey-flavoured placebo syrup every day for 1 month 2. Continue their usual treatment for allergic conjunctivitis and dry eye disease as prescribed by their eye doctor 3. Attend clinic visits for eye check-ups, including tests of tear film stability, dry eye symptoms, and eye surface health 4. Answer questionnaires about their eye symptoms and how these affect their daily activities and vision-related quality of life Participation is voluntary, and participants may stop taking part in the study at any time. Data collected up to the time they withdraw may still be used for research, but their routine medical care will not be affected
CONDITIONS
Official Title
Kelulut Honey for Allergic Conjunctivitis and Dry Eye Symptoms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18-40 years old
- Confirmed diagnosis of allergic conjunctivits
- Ocular surface disease index (OSDI) score > 12
- Compliance to conventional allergic conjunctivitis treatment
You will not qualify if you...
- Any corneal or ocular surface pathology
- Known diabetes mellitus or impaired glucose test
- Ocular surface disease due to trachoma or other inflammatory conditions
- Use of anti-inflammatory medications such as steroids, NSAIDS, oral doxycycline
- Concurrent use of other supplements or alternative therapies such as royal jelly, Manuka honey eye drop or omega-3 fatty acid
- Using preservative-containing topical eye drops for ocular problems other than allergic conjunctivitis
- History of ocular trauma/surgery or refractive surgery within last 3 years
- Wearing contact lens in the last 3 months
- Underlying inflammatory/systemic disease and connective tissue diseases
- Recent conjunctivitis in the last 3 months
- Patients on immunosuppressant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital Pakar Universiti Sains Malaysia
Kota Bharu, Kelantan, Malaysia, 16150
Actively Recruiting
Research Team
S
Sharifah Izzati Dr, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here